Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Azim · SciRah

Researcher profile · Semantic Scholar

H. Azim

Share profile

H. Azim — researcher profile on SciRah

h-index: 16
Works: 106
Citations: 1,166

Most-cited papers

Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies.
H. Azim, L. Santoro, N. Pavlidis, S. Gelber +3 more
2011European Journal of Cancer244 citations
Semantic Scholar
ESO-ESMO 5th International Consensus Guidelines for Breast Cancer in Young Women (BCY5).
S. Paluch-Shimon, F. Cardoso, A. Partridge, O. Abulkhair +19 more
2022Annals of Oncology215 citations Open access
Semantic Scholar
Clinicopathologic Features of Breast Cancer in Egypt—Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis
H. Azim, H. Elghazawy, R. Ghazy, A. Abdelaziz +3 more
2023JCO Global Oncology68 citations Open access
Semantic Scholar
Breast cancer in Egypt, China and Chinese: statistics and beyond.
H. Azim, A. S. Ibrahim
2014Journal of Thoracic Disease55 citations
Semantic Scholar
Treatment of breast cancer during pregnancy: regimen selection, pregnancy monitoring and more...
H. Azim, L. Del Mastro, G. Scarfone, F. Peccatori
2011Breast48 citations Open access
Semantic Scholar
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
J. Gligorov, B. Ataseven, M. Verrill, M. de Laurentiis +6 more
2017European Journal of Cancer45 citations Open access
Semantic Scholar
Survey of utilization of multidisciplinary management tumor boards in Arab countries.
N. E. El Saghir, Nadine S. El-Asmar, C. Hajj, T. Eid +10 more
2011Breast39 citations Open access
Semantic Scholar
Targeting mTOR in cancer: renal cell is just a beginning
H. Azim, H. Azim, B. Escudier
2010Targeted oncology39 citations
Semantic Scholar
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
M. de Laurentiis, S. Borštnar, M. Campone, E. Warner +14 more
2021Breast Cancer Research and Treatment38 citations Open access
Semantic Scholar
Abstract GS1-10: Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy
Yen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, H. Azim, Y. Eralp +9 more
2023Cancer Research37 citations
Semantic Scholar
Predicting Brain Metastasis in Breast Cancer Patients: Stage Versus Biology
H. Azim, R. Abdel-Malek, L. Kassem
2017Clinical Breast Cancer32 citations
Semantic Scholar
Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer
H. Azim, L. Kassem, I. Treilleux, Qing Wang +3 more
2016Translational Oncology32 citations Open access
Semantic Scholar
A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
Nabil Mubarak, R. Gaafar, S. Shehata, T. Hashem +5 more
2012BMC Cancer25 citations Open access
Semantic Scholar
Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)
H. Azim, A. Omar, H. Atef, H. Zawahry +7 more
2018Journal of Hepatocellular Carcinoma21 citations Open access
Semantic Scholar
Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup.
T. Rordorf, A. Hassan, H. Azim, Eniu Alexandru +15 more
2014Breast18 citations Open access
Semantic Scholar
The process of NCCN guidelines adaptation to the Middle East and North Africa region.
A. Jazieh, H. Azim, J. McClure, M. Jahanzeb
2010The Journal of the National Comprehensive Cancer Network17 citations Open access
Semantic Scholar
Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer
H. Elghazaly, H. Rugo, H. Azim, S. Swain +35 more
2021Cancers14 citations Open access
Semantic Scholar
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.
K. Jung, B. Ataseven, M. Verrill, X. Pivot +6 more
2018The Oncologist13 citations Open access
Semantic Scholar
Pathological Features and Prognosis of Lobular Carcinoma in Egyptian Breast Cancer Patients
H. Azim, R. Malek, A. Hatem
2014Women's Health13 citations Open access
Semantic Scholar
Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
H. Azim, K. Shohdy, H. Elghazawy, Monica M Salib +2 more
2022Biomarkers12 citations
Semantic Scholar
TNMF versus TNM in staging of colorectal cancer.
Ahmed Farag Ahmed Farag, M. Elbarmelgi, H. Azim, A. A. Abozeid +1 more
2016International Journal of Surgery10 citations Open access
Semantic Scholar
Commentary on "aTTom": long-term effects of continuing adjuvant Tamoxifen to 10 years.
H. Azim, Ahmed Saadeldeen
2014Chinese Clinical Oncology9 citations
Semantic Scholar
Managing pregnant women with cancer: personal considerations and a review of the literature
H. Azim, O. Gentilini, Marzia Locatelli, E. Ciriello +2 more
2011ecancermedicalscience9 citations Open access
Semantic Scholar
Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.
N. E. El Saghir, Y. Yap, Y. Eralp, S. Im +12 more
2023Journal of Clinical Oncology8 citations
Semantic Scholar
Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate!
H. Azim, N. Kamal, R. A. Malak
2013Journal of Thoracic Disease7 citations
Semantic Scholar
The Discrepancy Between High Pathological Complete Response (PCR) Rate and Low Breast Conserving Surgery (BCS) Following Neoadjuvant Therapy: Analysis from the Neoaltto Trial (BIG 1-06)
C. Criscitiello, H. Azim, D. Agbor-tarh, E. de Azambuja +6 more
20126 citations Open access
Semantic Scholar
Taxane-based regimens as adjuvant treatment for breast cancer: a retrospective study in egyptian cancer patients.
H. Azim, Yasser Salah El Din Abdal-Kader, M. Mousa, R. Malek +2 more
2015Asian Pacific Journal of Cancer Prevention5 citations Open access
Semantic Scholar
One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies
H. Azim, Sherif Ahmed Bahr, N. Kamal, Mohamed A. Koura +10 more
2013ecancermedicalscience5 citations Open access
Semantic Scholar
Safeher: A Study of Assisted- and Self-Administered Subcutaneous Trastuzumab (H-SC) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (EBC)
J. Gligorov, H. Azim, B. Ataseven, M. de Laurentiis +6 more
20125 citations Open access
Semantic Scholar
504 Safety of pregnancy in breast cancer survivors: a meta-analysis
H. Azim, L. Santoro, N. Pavlidis, F. Peccatori
20105 citations
Semantic Scholar
Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa region.
A. Bazarbachi, H. Azim, H. Alizadeh, M. Aljurf +13 more
2010The Journal of the National Comprehensive Cancer Network5 citations Open access
Semantic Scholar
Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis.
H. Azim, K. Shohdy, David F. Kaldas, L. Kassem +1 more
2020Current Problems in Cancer4 citations
Semantic Scholar
Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary results from the phase 3b CompLEEment-1 trial.
M. de Laurentiis, P. Neven, G. Jerusalem, T. Bachelot +13 more
20184 citations
Semantic Scholar
A multicenter, phase II study of the RAF-kinase inhibitor sorafenib in patients with advanced renal cell carcinoma.
H. Khaled, H. Azim, E. Barsoum, G. Chahine +6 more
2015Molecular and clinical oncology4 citations Open access
Semantic Scholar
P103 Subcutaneous trastuzumab plus chemotherapy for early breast cancer: interim safety from SafeHer
J. Gligorov, M. de Laurentiis, M. Verrill, K. Jung +6 more
20154 citations Open access
Semantic Scholar
Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.
C. Criscitiello, H. Azim, E. de Azambuja, I. Rubio
2014Annals of Oncology4 citations Open access
Semantic Scholar
Epidermal growth factor receptor mutation (EGFRMUT) in non-small cell lung cancer (NSCLC) in the Middle East.
A. Jazieh, H. Jaafar, R. S. Mustafa, K. Rasul +6 more
20134 citations
Semantic Scholar
Correlation Between Circulating Tumor Cells (CTCS), PET/CT Response And Pathological Complete Response (PCR) in Primary HER2-Positive (HER2+) Breast Cancer Patients: A Sub-Study From the Neoaltto Trial
H. Azim, F. Rothé, C. Aura, M. Bavington +6 more
20124 citations Open access
Semantic Scholar
The Abu Dhabi declaration: why the hustle?
H. Azim, A. Jazieh, M. Jahanzeb
2010The Journal of the National Comprehensive Cancer Network4 citations
Semantic Scholar
Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.
C. Criscitiello, H. Azim, E. de Azambuja, I. Rubio
2014Annals of Oncology3 citations Open access
Semantic Scholar
Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by an Expert Group from Middle East and North Africa Region
H. Azim, O. Ozyılkan, M. Seoud, Amal Ladjeroud +5 more
2022Current Women's Health Reviews2 citations Open access
Semantic Scholar
Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC).
M. de Laurentiis, S. Borštnar, M. Campone, E. Warner +14 more
20202 citations
Semantic Scholar
Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC).
M. de Laurentiis, S. Borštnar, M. Campone, E. Warner +14 more
2019Journal of Clinical Oncology2 citations
Semantic Scholar
Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial.
C. Zamagni, M. Campone, I. Kudryavcev, U. Brown-Glaberman +9 more
2018Annals of Oncology2 citations Open access
Semantic Scholar
Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial.
R. Hui, A. Pearson, J. C. Castán, C. Campbell +16 more
2018Annals of Oncology2 citations Open access
Semantic Scholar
Abstract P6-04-13: The role of precision medicine in "real-life" management of breast cancer patients: A survey assessing the current use and attitudes towards tumor molecular sequencing in clinical practice
I. Gingras, A. Sonnenblick, S. Dolci, E. de Azambuja +6 more
20162 citations
Semantic Scholar
21 Pregnancy Following Estrogen Receptor-Positive Breast Cancer is Safe – Results From a Large Multi-center Case-control Study
H. Azim, N. Kroman, L. Ameye, N. Rotmensz +6 more
20122 citations
Semantic Scholar
Elucidating the biological basis of prognosis in young women with early breast cancer (BC) using gene expression profiling.
H. Azim, S. Michels, Philippe Bédard, D. Fumagalli +5 more
2011Journal of Clinical Oncology2 citations
Semantic Scholar
Genetic testing for BRCA1/2 variants in Northern African women with ovarian and breast cancers: a multicentre study of an under-represented ancestry
K. Shohdy, L. Kassem, T. Elnahas, E. Barsoum +5 more
2025ESMO Open1 citations Open access
Semantic Scholar
Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial
H. Azim, M. Saleh, Passant Essam Eldin, Ahmed A. M. Abdelhafeez +2 more
2024Journal of chemotherapy1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Kassem×7
Invite
L. Kassem — researcher profile on SciRah
M. de Laurentiis×7
Invite
M. de Laurentiis — researcher profile on SciRah
F. Peccatori×6
Invite
F. Peccatori — researcher profile on SciRah
Ji-Wen Wu×6
Invite
Ji-Wen Wu — researcher profile on SciRah

×6

Invite

E. de Azambuja — researcher profile on SciRah

Invite

J. Gligorov — researcher profile on SciRah

Invite

P. Cottu — researcher profile on SciRah

Invite

C. Zamagni — researcher profile on SciRah

Invite

B. Ataseven — researcher profile on SciRah

Invite

K. Jung — researcher profile on SciRah

Invite

X. Pivot — researcher profile on SciRah

N. E. El Saghir×4

Invite

N. E. El Saghir — researcher profile on SciRah